AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
PHOENIX -- Risedronate therapy reduces the risk of vertebral fractures among osteoporotic patients in as little as 6 months, according to an analysis of data from two large studies.
The analysis, which included 2,442 women, showed a fracture incidence rate of 0.1% over the first 6 months of treatment in those receiving 5 mg risedronate daily, compared with a 1% rate in those treated with placebo, Dr. Nelson B. Watts said at the annual meeting of the American Society for Bone and Mineral Research.
The finding underscores the importance of treating patients who have had a vertebral fracture, since without treatment one in five will have another fracture in the following year, said Dr, Watts, director of the osteoporosis center at the University of Cincinnati, in an interview.
"This is a post-hoc analysis, but it does provide information that the drug works early," he said. "There was even a difference at 3 months, but there were so few fractures that it was not statistically significant."
At 9 months, the analysis found a ...